Yet, key anti-viral responses such as IFNG primarily produced by cytotoxic T cells were spared (Extended data Fig. 5a), highlighting the selective effects of combined anti-IFNAR2/Remdesivir therapy on chronic COVID-19 pathology. The gene discussed is IFNAR2; the disease is COVID-19.